We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

116 hedge funds and large institutions have $122M invested in Oramed Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 15

177% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 13

125% more call options, than puts

Call options by funds: $5.67M | Put options by funds: $2.52M

25% more funds holding

Funds holding: 93 → 116 (+23)

5.87% more ownership

Funds ownership: 16.65% → 22.52% (+5.9%)

3% more capital invested

Capital invested by funds: $119M → $122M (+$3.34M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
116
Holders Change
+23
Holders Change %
+24.73%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
36
Increased
44
Reduced
15
Closed
13
Calls
$5.67M
Puts
$2.52M
Net Calls
+$3.15M
Net Calls Change
-$1.84M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$14.5M
2
Citadel Advisors
Citadel Advisors
Florida
+$10.8M
3
Two Sigma Investments
Two Sigma Investments
New York
+$8.41M
4
Morgan Stanley
Morgan Stanley
New York
+$5.57M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$4.75M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$15.5M
2
JC
Jetstream Capital
Tennessee
-$2.64M
3
EI
EAM Investors
California
-$1.46M
4
SM
Sabby Management
Florida
-$887K
5
Man Group
Man Group
United Kingdom
-$820K
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
26
Swiss National Bank
Switzerland
$920K +$1.35M +64,400 New
HF
27
HRT Financial
New York
$916K +$1.34M +64,198 New
Jane Street
28
Jane Street
New York
$875K +$166K +7,930 +15%
Barclays
29
Barclays
United Kingdom
$783K +$496K +23,740 +76%
RPC
30
Rossmore Private Capital
Connecticut
$743K +$105K +5,000 +11%
EMG
31
ETF Managers Group
New Jersey
$729K +$67.5K +3,229 +6%
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$725K +$521K +24,932 +96%
CSS
33
Cubist Systematic Strategies
Connecticut
$722K +$1.06M +50,576 New
OQS
34
Occudo Quantitative Strategies
Florida
$657K +$32.2K +1,542 +3%
AGM
35
Alpine Global Management
New York
$614K +$899K +43,013 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$593K +$525K +25,129 +153%
OC
37
Oppenheimer & Co
New York
$571K +$109K +5,200 +15%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$567K +$830K +39,700 New
Squarepoint
39
Squarepoint
New York
$563K +$824K +39,433 New
OMC
40
Old Mission Capital
Illinois
$553K +$809K +38,691 New
BHCM
41
Boulder Hill Capital Management
New York
$551K +$807K +38,600 New
Walleye Capital
42
Walleye Capital
New York
$525K +$768K +36,740 New
JP Morgan Chase
43
JP Morgan Chase
New York
$499K +$497K +23,749 +212%
E
44
Ergoteles
New York
$483K +$707K +33,800 New
PF
45
Phoenix Financial
Israel
$439K +$56.9K +2,722 +10%
Ameriprise
46
Ameriprise
Minnesota
$417K -$90.4K -4,325 -13%
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
$386K – – –
Osaic Holdings
48
Osaic Holdings
Arizona
$375K +$182K +8,697 +49%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$349K +$46.2K +2,212 +10%
JF
50
Jump Financial
Illinois
$346K +$506K +24,206 New
1
2
3 4 5

ORMP Hedge Fund Activity: Q4 2021 in Review

116 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2021, worth a combined $122M — up 2.8% from $119M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ORMP positions and 13 closed out — a net gain of 23 holders — while 44 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, adding an estimated $14.5M. The largest seller was Invesco, cutting an estimated $15.5M.

  • 116 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2021, up from 93 in Q3 2021.
  • Funds reported $122M of Oramed Pharmaceuticals stock for Q4 2021, up 2.8% quarter-over-quarter.
  • 36 funds opened new Oramed Pharmaceuticals positions in Q4 2021 and 13 closed out, a net change of +23 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2021 was Millennium Management, an estimated $14.5M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2021 was Invesco, an estimated $15.5M sold.

Based on aggregated 13F filings for Q4 2021.